SOPs for Drug Discovery

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for collaborating with external preclinical testing laboratories. Collaborating with external labs is a common practice in drug development when specialized expertise, resources, or services are required that are not available internally. This SOP ensures that such collaborations are managed effectively, ensuring that all data generated by external labs meet quality standards, regulatory requirements, and project timelines.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedures for the use of alternative models in preclinical studies. Alternative models are crucial for reducing, refining, and replacing the use of animals in research while still providing scientifically valid data. These models may include in vitro systems, computer models, human-derived cell cultures, and other non-animal testing approaches. This SOP ensures that the use of alternative models is conducted systematically, in compliance with ethical guidelines, and provides data that is reliable for regulatory submissions and safety evaluations.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to establish guidelines for ensuring the quality of data generated during preclinical studies. Data quality is crucial for making informed decisions during drug development, ensuring regulatory compliance, and maintaining scientific integrity. This SOP ensures that data generated in preclinical studies are accurate, reproducible, and compliant with Good Laboratory Practice (GLP) standards, providing a solid foundation for regulatory submissions and clinical development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for analyzing protein binding in drug development. Protein binding is a critical pharmacokinetic property that influences the distribution, metabolism, and elimination of a drug. This SOP ensures that protein binding studies are conducted systematically and in compliance with regulatory guidelines, providing accurate and reproducible data that will inform drug dosing, safety, and efficacy evaluations in preclinical and clinical stages.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for conducting phototoxicity testing in preclinical studies. Phototoxicity testing is essential for assessing the potential of a drug or chemical compound to cause harmful effects in tissues when exposed to light, particularly ultraviolet (UV) radiation. This SOP ensures that phototoxicity studies are conducted in compliance with regulatory guidelines and Good Laboratory Practice (GLP) standards, providing valuable data for the safety evaluation of new drug candidates before clinical trials.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for preparing preclinical dossiers required for regulatory submissions. These dossiers include essential data from preclinical studies that demonstrate the safety, pharmacokinetics, and efficacy of a drug candidate. This SOP ensures that all preclinical data are compiled, analyzed, and presented in accordance with regulatory requirements, providing a comprehensive and accurate dossier for submission to regulatory authorities such as the FDA or EMA.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedures for conducting biodistribution studies. These studies are crucial for assessing the distribution, localization, and concentration of a drug or its metabolites within various tissues and organs after administration in animal models. Biodistribution data are essential for understanding the pharmacokinetics of a drug, evaluating its therapeutic potential, and determining its safety profile before clinical trials. This SOP ensures that biodistribution studies are conducted according to regulatory guidelines and GLP standards, with appropriate documentation and data analysis.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for performing pharmacokinetic (PK) and pharmacodynamic (PD) modeling in preclinical studies. PK/PD modeling is essential for understanding the relationship between drug concentration and pharmacological effect. This SOP ensures that PK/PD modeling is conducted systematically, using appropriate mathematical models to predict in vivo drug behavior, optimize dosing regimens, and inform the transition to clinical studies.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedures for conducting translational studies that bridge preclinical and clinical phases of drug development. Translational studies aim to apply preclinical findings to clinical settings, thereby improving the prediction of clinical outcomes and optimizing the transition from animal models to human trials. This SOP ensures that translational studies are designed, executed, and documented in accordance with regulatory guidelines, internal protocols, and scientific standards to maximize the relevance and applicability of preclinical data in clinical settings.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for performing pharmacokinetic (PK) and pharmacodynamic (PD) modeling in preclinical studies. PK/PD modeling is essential for understanding the relationship between the drug concentration and its pharmacological effect. This SOP ensures that PK/PD modeling is conducted systematically to predict the drug’s behavior in vivo, optimize dosing regimens, and inform the transition to clinical studies.
Click to read the full article.